Register for OBR daily


FM_ROS_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

TLOG $5.05 0.7500 +17.44%
AGEN $3.93 0.5750 +17.16%
MGNX $33.83 4.5800 +15.66%
DRNA $15.94 1.9000 +13.53%
KPTI $36.12 3.5100 +10.76%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BDSI $13.06 -0.9000 -6.45%
PARD $0.16 -0.0100 -5.88%
TGTX $15.70 -0.7200 -4.38%
BIND $5.49 -0.2500 -4.36%
BLRX $1.69 -0.0500 -2.87%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

Promedior Presents Positive Phase 2 Data For PRM-151 in Myelofibrosis at ASH Annual Meeting

(MarketWatch) Dec 9, 2014 - Promedior, Inc., today announced positive data from Stage 1 of an adaptive two-stage Phase 2 trial of PRM-151, a novel anti-fibrotic immunotherapy, in patients with myelofibrosis.
read article 



Takeda Presents Phase 2 Data on Maintenance With Single-Agent Investigational Ixazomib in Patients With Newly Diagnosed Multiple Myeloma

(Yahoo! Finance) Dec 9, 2014 - Takeda Pharmaceutical Company Limited today announced results from an open-label, Phase 2 study evaluating the safety and efficacy of oral, single-agent ixazomib (MLN9708) as maintenance therapy in patients with multiple myeloma (MM) who had received ixazomib, lenalidomide and dexamethasone as induction therapy.
read article 



Kiadis Pharma Presents Positive Data From a Pre-Specified Interim Analysis of the Phase II Clinical Program With Its Lead Product ATIR™

(TheStreet) Dec 9, 2014 - Kiadis Pharma B.V. today announces positive interim data from the ongoing Phase II clinical study with its lead product ATIR™.
read article 



CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells

(CNNMoney) Dec 9, 2014 - CTI BioPharma Corp. today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays.
read article 



Seattle Genetics Presents ADCETRIS® (Brentuximab Vedotin) Data in Diffuse Large B-Cell Lymphoma at ASH Annual Meeting

(Seattle Genetics) Dec 8, 2014 - Seattle Genetics, Inc. today highlighted two separate ADCETRIS (brentuximab vedotin) data presentations in relapsed/refractory and frontline diffuse large B-cell lymphoma (DLBCL) at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Francisco, CA, December 6-9, 2014.
read corporate press release 



Seattle Genetics Presents Data From Novel Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting

(Seattle Genetics) Dec 8, 2014 - First clinical data presentation of SGN-CD33A demonstrates encouraging antitumor activity in Acute Myeloid Leukemia; dose and schedule refinement ongoing; phase 1b combination trial planned to evaluate SGN-CD33A with standard of care in frontline and consolidation settings for Acute Myeloid Leukemia.
read corporate press release 



Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients With Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

(Pharmacyclics) Dec 9, 2014 - Pharmacyclics, Inc. today announced new, longer term data in IMBRUVICA® (ibrutinib) patients with relapsed/refractory chronic lymphocytic leukemia (CLL), including high-risk CLL patients with deletion 17p (del 17p).
read corporate press release 



IMBRUVICA® (ibrutinib) Shows Sustained Progression-Free Survival in Patients With High-Risk Chronic Lymphocytic Leukemia With Genetic Mutation

(TheStreet) Dec 8, 2014 - Results from the Phase 2 RESONATE ™-17 (PCYC-1117) study show IMBRUVICA® (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).
read article 



IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma

(Yahoo! Finance) Dec 8, 2014 - New, 27-month IMBRUVICA® (ibrutinib) median follow-up data announced by Pharmacyclics, Inc. today support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma (MCL), an aggressive type of lymphoma.
read article 



IMBRUVICA® (ibrutinib) Long-Term Follow-Up Data in Patients Living With Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive at Two Years

(Johnson & Johnson) Dec 8, 2014 - Follow-up data from the Phase 2 PCYC-1104 trial presented at the American Society of Hematology Annual Meeting show sustained efficacy and safety over time.
read corporate press release 



Combination of ISTODAX® (romidepsin) and Standard CHOP Demonstrates a Complete Response in 51% of Patients With Peripheral T-Cell Lymphoma

(NASDAQ) Dec 9, 2014 - Celgene Corporation today announced that data were presented from a phase 1b/2 study of ISTODAX® (romidepsin) combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with peripheral t-cell lymphoma were presented during the 56th American Society of Hematology annual meeting.
read article 



Juno’s CAR T and TCR Investigational Product Candidates Demonstrate Promising Outcomes in Clinical Trials in Patients With B-Cell Cancers

(CNBC) Dec 8, 2014 - Juno Therapeutics, Inc. announced today that clinical data from its most advanced chimeric antigen receptor (CAR) product candidates, JCAR017, JCAR015 and JCAR014, demonstrated encouraging evidence of clinical responses in acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL).
read article 



Amgen Presents Data From Pivotal Phase 2 Study of BLINCYTOTM (blinatumomab) Immunotherapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

(MarketWatch) Dec 8, 2014 - Secondary analysis demonstrates 40 percent of patients who achieved complete remission were enabled to proceed to stem cell transplant.
read article 



Data Presented on REVLIMID® (lenalidomide) Compared With Investigators' Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

(Celgene) Dec 8, 2014 - Celgene Corporation today announced that results were presented from a phase II/III study (DLC-001) of REVLIMID® (lenalidomide) compared with investigators' choice (IC) of therapy in patients with relapsed/refractory diffuse large b-cell lymphoma (DLBCL) were presented during the 56th American Society of Hematology annual meeting.
read corporate press release 



REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH

(Celgene) Dec 8, 2014 - Celgene Corporation today announced results from studies of REVLIMID® (lenalidomide) and the combination of lenalidomide plus rituximab in patients with mantle cell lymphoma (MCL), which were presented during the 56th American Society of Hematology annual meeting.
read corporate press release 



Additional Analyses of High-Risk Patients From Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH

(Celgene) Dec 8, 2014 - Celgene Corporation today announced that data from two sub-group analyses from AML-001, its phase III study of VIDAZA® (azacitidine for injection) compared with conventional care regimens (CCR) in elderly subjects with newly diagnosed acute myeloid leukemia (AML, > 30% blasts), were presented at the 56th American Society of Hematology annual meeting.
read corporate press release 



Results From Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plus Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Presented at ASH

(NASDAQ) Dec 8, 2014 - Celgene Corporation today announced that results from the STRATUS™ trial (MM-010), a single-arm phase IIIb study of pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma were presented at the 56th American Society of Hematology annual meeting.
read article 



New Data at ASH 2014 Highlight Progress of Pfizer’s Growing Portfolio in Blood Cancers

(CNBC) Dec 9, 2014 - Pfizer Inc. today announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML).
read article 



Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data From ADCETRIS(R) (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting

(Yahoo! Finance) Dec 9, 2014 - Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001).
read article 



Acceleron/Celgene Two-Pronged Attack on Rare Blood Disorders

(PharmaTimes [UK]) Dec 8, 2014 - Acceleron Pharma and Celgene Corp have unveiled positive mid-stage data at the American Society of Hematology meeting in San Francisco on two compounds - luspatercept and sotatercept - which are being developed to target rare blood disorders.
read article 



Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTOTM (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

(MarketWatch) Dec 8, 2014 - Secondary analysis demonstrates 40 percent of patients who achieved complete remission were enabled to proceed to stem cell transplant.
read article 



Results from Phase IIIb Study of POMALYST®/IMNOVID® (pomalidomide) Plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Presented at ASH

(NASDAQ) Dec 8, 2014 - Celgene Corporation today announced that results from the STRATUS™ trial (MM-010), a single-arm phase IIIb study of pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma were presented at the 56th American Society of Hematology annual meeting.
read article 



Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS(R) (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting

(Yahoo! Finance) Dec 9, 2014 - Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received ADCETRIS (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively; hazard ratio=0.57; p-value=0.001).
read article 



First Top-flight Evidence of TKI Benefit in AML

(Medscape Medical News) Dec 8, 2014 - Adding sorafenib (Nexavar, Onyx) to standard chemotherapy improves relapse-free and event-free survival in younger patients with newly diagnosed acute myeloid leukemia (AML), according to a new study.
read article (free registration required) 



Scottish Patients Get Access to Roche's CLL Drug on NHS

(PharmaTimes [UK]) Dec 8, 2014 - From today patients in Scotland with chronic lymphocytic leukaemia (CLL) have gained ‘routine’ access to a new treatment option after cost-regulators approved Roche’s Gazyvaro (obinutuzumab) for National Health Service use in the country.
read article